Lupus & antiphospholipid syndrome
Patient perspectives on Systemic Lupus Erythematosus (SLE), refractory Antiphospholipid Syndrome (APS), and biologic drug use during pregnancy
Authors' conclusion
Most women would accept adverse obstetric outcomes or maternal complications as long as pregnancy results in a live birth. The majority of respondents consistently expressed a desire for additional medication to reduce the risk of complications during pregnancy, regardless of the specific complication at hand.
Study context
- Population
- Female members of the Dutch National Patient Association for Lupus Erythematosus with SLE and/or APS (mean age 39); 42% APS, 31% SLE, 27% both
- Participants
- 71 respondents
- Outcome
- Perspectives on pregnancy complications and additional medication use
Methodological detailsonline questionnaire, scenario-based survey, Survey ran from November 18, 2023, to March 19, 2024, Eight potential pregnancy complication scenarios presented
- Online questionnaire
- Scenario-based survey
- Survey ran from November 18, 2023, to March 19, 2024
- Eight potential pregnancy complication scenarios presented
Main finding
As reported in the abstract
Would endure pregnancy complications (e.g. SLE flare or pre-eclampsia) for a live-born baby
79%
Willingness to use additional medication, varying by complication scenario
51%-89%
Observational data: associations, not effects.
Original publication
Patient perspectives on SLE, refractory APS, and biologic drug use during pregnancy. Lupus. Published 26 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →